根据最新提交至美国证券交易委员会的文件显示，医疗保健巨头康西哥明确表示，计划重申其2026年财务目标。公司预计届时按通用会计准则计算的稀释后每股收益将突破1.98美元，而经调整后的每股收益更是瞄准超过3.00美元的重要关口。
这一指引的确认，凸显了管理层对中长期盈利能力的坚定信心。尽管医疗行业面临政策变动与成本压力，康西哥通过精细化运营和战略布局，展现出持续创造股东价值的强大韧性。值得注意的是，双重每股收益指标的设定，为投资者提供了更全面的业绩评估维度，既包含标准财务表现，又反映剔除特殊项目后的核心运营成果。
随着2026年时间节点的临近，市场将密切关注该公司如何通过业务优化与技术创新实现这些雄心勃勃的目标。此次指引重申不仅巩固了资本市场对企业的预期，更传递出管理层对未来增长轨迹的精准把控能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.